BioMarin Recommended on Weakness and 4 Stock Analyses to Note

MAKO Surgical Corp. (NASDAQ:MAKO) is predicted by Piper Jaffray to preannounce Q4 results on Monday morning, January 7, and the firm recommends that investors purchase the stock before the release. Piper continues to believe that in-line volumes and robots of 3,100, and 16 should ease investor concerns and drive the stock higher.

Accuray Incorporated (NASDAQ:ARAY): According to Jefferies, the company’s weaker than expected Q2 results along with its lowered FY13 outlook came as no surprise. However, what was surprising was the severity of the downside. The firm’s Buy thesis on the stock continues be be intact, and the firm keeps a Buy rating and reduced its price target to $6.50 from $10 on the stock.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

Bonanza Creek Energy¬†(NYSE:BCEI) target has been raised by RBC Capital since the company provided higher than expected 2013 production guidance, considering management’s increased confidence regarding the Wattenberg Niobrara/Codell formations. The firm has decided to keep its Sector Perform rating on the stock.

Family Dollar Stores Inc. (NYSE:FDO) target has been lowered by RBC Capital following the company’s reporting of lower Q1 EPS than previously predicted. The firm is convinced that the company was forced to deal with margin pressures last quarter, but it keeps its bullish regarding the stock’s long-term outlook, and it reiterates its Outperform rating on the stock.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is recommended by RBC Capital to be purchased on any weakness if the company chooses not to continue to develop its BMN-701 drug after it reports its Phase II data on February 15, due to the firm’s belief that the drug isn’t key to the company’s success. The firm keeps its upbeat stance on BioMarin’s outlook and maintains its Outperform rating on the stock.

Investing Insights: Is Avon the Next Herbalife?